Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
2don MSN
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback